
Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.
Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.
Regardless of the cause of bias, more awareness and scrutiny are needed when utilizing cost-effectiveness studies for healthcare decision making.
Published: February 16th 2017 | Updated:
Published: December 18th 2012 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.